Our story

AIQ Solutions was born out of the University of Wisconsin Translational Imaging Research Program. The original founders, Robert Jeraj, PhD; Glenn Liu, MD; George Wilding, MD; and Dona Alberti, BSN, RN, had worked together for over ten years at the University of Wisconsin Carbone Cancer Center and had decades of experience in drug development, clinical trials and translational imaging research.

From 2009 to 2015, Dr. Jeraj and Dr. Liu leveraged $8M in industry and grant funding to develop the novel methodology underlying AIQ's products. In January 2015 AIQ was incorporated. The patents protecting AIQ’s innovations were issued in October 2015 and March 2017. In April 2017 AIQ signed an exclusive license agreement with the Wisconsin Alumni Research Foundation covering both patents as well as the software code associated with QTBI. In July 2018 AIQ received US FDA 510(k) clearance for its QTxI platform, which includes the QTBI product.

Dr. Glenn Liu (left) and Dr. Robert Jeraj (right). Image courtesy UW Carbone Cancer Center's 2012 Annual Report

Dr. Jeraj and Dr. Liu are recognized globally as experts in their fields. Both continue to do groundbreaking research, Dr. Jeraj as the director of the Wisconsin Oncology Network of Imaging Excellence and Dr. Liu as the leader of the developmental therapeutics program at the University of Wisconsin Carbone Cancer Center. Both also continue to provide company leadership as AIQ’s CSO and CMO, respectively. Ms. Alberti brings her 20 years of clinical research experience to AIQ as COO. Guy Starbuck joined the founder team in 2016 as CTO. Mr. Starbuck is a software architect with over 20 years of commercial software development, including more than a decade managing the development of software in regulated industries.

In September 2018 Eric Horler joined AIQ as CEO, bringing 14 years of experience in medical product development, marketing, sales, and general management. AIQ Solutions is now poised for rapid growth with a strong leadership team, one product fully commercialized, and a strong pipeline of new products at varying stages of development.

Interested in supporting us as we REvolutionizE the treatment of complex disease?

Learn about investment opportunities